Rationale: Myocardial infarction (MI) is a leading cause of death worldwide. Because endogenous cardiac repair mechanisms are not sufficient for meaningful tissue regeneration, MI results in loss of cardiac tissue and detrimental remodeling events. MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression in a sequence dependent manner. Our previous data indicate that miRNAs are dysregulated in response to ischemic injury of the heart and actively contribute to cardiac remodeling after MI.
I schemic heart disease can lead to congestive heart failure, which is the leading cause of death worldwide. 1 Ischemic heart disease is induced by an insufficient oxygen supply to the myocardium, typically due to coronary artery disease or myocardial infarction (MI). During an MI, occlusion of coronary vessels impedes a sufficient oxygen supply to the heart muscle and the resulting hypoxia results in loss of viable cardiac tissue, which often correlates with impairment of cardiac contractility. In response to ischemic injury, the nonischemic myocardium displays signs of secondary remodeling, such as interstitial fibrosis and hypertrophy of cardiac myocytes, which further diminish pump function and increase susceptibility to arrhythmias. Currently, the most effective strategy for reducing the size of a myocardial infarct and improving the clinical outcome after an acute MI is early myocardial reperfusion by either thrombolytic therapy or primary percutaneous coronary intervention. Cardiac cell therapy as a means of regenerating the infarcted heart has made substantial progress. In recent years, randomized, controlled clinical trials have demonstrated that cell therapy can improve cardiac function in patients after MI. However, current limitations for cell therapy are the low rates of cell engraftment after intracoronary delivery and poor cell survival after intramyocardial injections. 2 Data from us and others have indicated that microRNAs (miRNAs) play important roles during different forms of heart disease. Previously, we showed that miRNAs are dysregulated in response to MI and contribute to the cardiac remodeling process induced by infarction. 3 MiR-NAs are short, 21-to 25-nucleotide noncoding RNAs that modulate gene expression by base pairing with the 3Ј untranslated regions of mRNAs, and inducing mRNA degradation or translational inhibition of the target. Nucleotides 2-8 of the 5Ј end of the miRNA, called the "seed sequence," are especially important for mRNA target interaction. Interestingly, most miRNAs belong to families of closely related miRNAs with homologous seed sequences while differing in their 3 portion. 4 Because the seed region is conserved, miRNA family members can presumably regulate overlapping target genes.
We show the dynamic pattern of miRNA expression in a porcine model of ischemic damage both short term and long term after injury. Especially intriguing is the upregulation of a family of miRNAs, called the miR-15 family, in the infarct region on ischemic injury. The miR-15 family consists of multiple miRNAs (miR-15a, miR-15b, miR-16 -1, miR-16 -2, miR-195, and miR-497) and is consistently found to be upregulated in different settings of heart disease (reviewed in Small et al 5 ) . Although the cardiac functions of this miRNA family have not been previously defined in vivo, these miRNAs are predicted to influence cardiomyocyte cell survival by regulating the expression of several prosurvival proteins, including Arl2 and Bcl2. 6, 7 The use of chemically modified, single-stranded oligonucleotides has been shown to be effective in inactivating specific miRNAs in vivo through complementary base pairing. 8 -13 Our data show that LNA-modified anti-miR chemistries can effectively silence miR-15 family members in vitro and render cardiomyocytes resistant to hypoxia-induced cardiomyocyte cell death. Correspondingly, systemic delivery of a miR-15 anti-miR dose-dependently represses miR-15 family members in both murine and porcine cardiac tissue, whereas therapeutic dosing of anti-miR chemistries targeting miR-15 in mice reduces infarct size, inhibits cardiac remodeling, and enhances cardiac function in response to ischemic damage. These studies represent an important step toward optimization of oligonucleotide-based therapies for modulation of cardiac miRNAs, and validate miR-15 as a therapeutic target for the manipulation of cardiac remodeling and function in the settings of ischemic heart disease.
Methods
An expanded Methods section describing all procedures and protocols is available in the Online Data Supplement at http://circres.ahajournals.org.
Animals
All animal studies were reviewed and approved by the Animal Care and Use Committee (IACUC) at miRagen Therapeutics, Inc (murine studies) or the University of Miami IACUC (porcine ischemiareperfusion study) and comply with Federal and State guidelines concerning the use of animals in research and teaching as defined by The Guide For the Care and Use of Laboratory Animals (NIH Publication No. 80 -23, revised 1985) . The porcine dose-ranging studies were done by AccelLAB (Boisbriand, Canada), which is accredited by the Canadian Council on Animal Care (CCAC) and complies to IACUC requirements and to those of the Guide for the Care and Use of Laboratory Animals of the United States Department of Agriculture (USDA).
Ischemia-Reperfusion Surgery
Female Yorkshire pigs (3 months of age; weight, 25-30 kg; nϭ4) were subjected to MI by inflation of a coronary angioplasty balloon in the left anterior descending artery for 60 minutes, followed by reperfusion. Ischemia-reperfusion in male C57Bl6 adult mice (8 -10 weeks of age) was induced by 75 minutes of left coronary artery occlusion followed by reperfusion for either 24 hours or 2 weeks as described previously. 14 More details can be found in the on-line Data Supplement.
Microarray for miRNAs and mRNAs
Microarray analysis was performed on total RNA, using a service provider (LC Sciences, Houston, TX) as described previously. 3 Detailed description can be found in the on-line Data Supplement.
Real-Time PCR
Total RNA from cardiac tissue was isolated using Trizol (Invitrogen). RT-PCR with random hexamer primers (Invitrogen) was performed on RNA samples, after which the expression of a subset of genes was analyzed by either a regular or quantitative real-time PCR, using gene-specific primers or Taqman probes purchased from ABI. For quantitative real-time PCR, a pool of synthetic microRNAs was used to generate a standard curve. Manufacturer's instructions were followed for the standard curve starting concentration and subsequent serial dilution (Ambion miRvana reference library).
Cell Culture and Luciferase Assay
HeLa cells and neonatal cardiomyocytes were cultured as described previously. 15 Transfection experiments in HeLa cells for luciferase assays were performed according to the manufacturer's instructions. More details can be found in the on-line Data Supplement.
Model of Hypoxia and Reoxygenation
Immediately after transfection, cells were placed in either a low oxygen atmosphere or normoxic conditions. To induce hypoxia, cells were incubated in a humidified environment at 37°C in a 3-gas hypoxic chamber maintained at 5% CO 2 and 0.2%O 2 (oxygen expelled by nitrogen) for 72 hours. Normoxic cells were maintained in 2% serum in a normoxic incubator (21% O 2 , 5% CO 2 , 37°C). After 72 hours of hypoxia, cells were exposed to 3 hours of reoxygenation under normoxic conditions and in media containing 2% serum.
Myocyte Survival Assays
After exposure to normoxia, hypoxia, or hypoxia plus reoxygenation for the indicated periods of time, several detection methods were used to determine apopotosis/cell survival. A detailed description can be found in the online Data Supplement.
Intravenous Delivery of LNA-Modified Anti-miRs
The LNA-anti-miR oligonucleotides were synthesized at miRagen Therapeutics, Inc as unconjugated and fully phosphorothiolated oligonucleotides. The perfectly matching LNA-anti-miR oligonucleotide was complementary to the 5Ј region of the mature miR-15b . The LNA control oligonucleotide consisted of a sequence directed against a Caenorhabditis elegans miRNA that is not expressed in mammals. Eight-to 10-week-old C57BL/6 mice or young pigs were injected intravenously with the indicated doses of anti-miR, universal control, or a comparable volume of saline, after which tissues were collected at the indicated time points.
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Northern Blot Analysis
Total RNA was isolated from porcine or mouse cardiac tissue samples by using Trizol reagent (Gibco/BRL). Northern blot analysis for the experiments in which LNA-modified anti-miR chemistries were used were performed on nondenaturing gels to show the heteroduplex formation between the LNA and mature miRNAs, as described previously. 9
Tissue and Plasma Distribution Assay
Levels of anti-miRs in plasma or tissues were measured using a hybridization assay method to detect the L/D 15b. A competition assay was used to detect tiny 15b. Detailed descriptions can be found in the online Data Supplement.
Infarct Size Determination
After 24 hours of reperfusion, the mice were anesthetized and the left main coronary artery ligation site was identified and religated. Evans Blue dye (1.2 mL of a 2.0% solution, Sigma) was injected through a carotid artery catheter into the coronary circulation to delineate the ischemic zone from the nonischemic zone. Triphenyltetrazolium chloride (Sigma) was used to demarcate the viable and nonviable myocardium within the ischemic zone. More details can be found in the online Data Supplement.
Echocardiography
Cardiac function and heart dimensions were evaluated by 2-dimensional echocardiography in mice sedated with 5% isoflurane using a Visual Sonics Vevo 770 Ultrasound (Visual Sonics, Toronto, Canada), as described. 16 More details can be found in the online Data Supplement.
Statistical Analysis
One-way ANOVA and Newman-Keuls multiple comparison posttest or a t test were used to determine significance. PϽ0.05 was considered statistically significant.
Results miRNAs Are Dynamically Regulated in Response to Ischemia-Reperfusion Injury
Based on recent data showing miRNA dysregulation during cardiac remodeling, we set out to examine whether miRNAs are also involved in ischemia-reperfusion injury of the porcine heart. To this end, we performed miRNA microarray analysis on porcine cardiac samples both 2 and 8 weeks after ischemia-reperfusion injury and profiled miRNA expression in the infarct and border zone regions post-MI compared with control tissue from sham-operated animals. The data showed a distinct miRNA expression signature and indicated that miRNAs are dynamically regulated in different regions of the porcine heart during post-MI remodeling, which could be confirmed by miRNA-specific real-time PCR analysis (Supplemental Tables I and II and Supplemental Figure I, A) . Although many of the regulated miRNAs have previously been implicated in cardiac disease, several dysregulated miRNAs had so far not been connected to cardiac disease ( Supplemental Tables I and II) . Because infarct healing is a dynamic process involving specific regional and temporal changes in cardiomyocyte hypertrophy, apoptosis, and fibrosis, we next assessed the regulation of these miRNAs more acutely after MI. Realtime analysis confirmed the regulation of specific miRNAs in the infarcted and borderzone region 24 hours after the ischemic injury (Supplemental Figure IB) . Interestingly, all members of the miR-15 family (miR-15a, -15b, -16, -195, and -497) were found to be upregulated in the infarcted region 24 hours after ischemic injury in the porcine MI model, as assessed by both real-time PCR analysis and Northern blot ( Figure 1A and 1B) . Although the signal for the loading control was reduced in the infarcted region (U6), probably because of the loss of viable cells, there was a significant increase in miR-15b. Of the miR-15 family, only miR-15b was still elevated 
Anti-miR-Mediated miR-15b Inhibition In Vitro
The miR-15 family members are expressed as 3 bicistronic clusters (Supplemental Figure II) , and all contain a comparable seed sequence (Figure 2A ). Although all 3 clusters are expressed in the heart, miR-16 is most abundant and miR-497 has the lowest expression, as determined by absolute copy number per cell in vivo (Ϸ10 000 copies versus 300 copies per cardiac cell) (Supplemental Figure  III, A) . In vitro analysis of the different miR-15 family members indicates a comparable relative abundance for the different members in fibroblasts and myocytes, albeit at a much lower level than they are detected at in vivo (Supplemental Figure III, B ). Because the miR-15 family has been implicated in apoptosis, 17 we hypothesized that elevated levels of miR-15 family members in response to ischemic injury might contribute to a decrease in viable cardiomyocytes. To develop an efficient approach for miR-15 targeting in vivo, we evaluated the in vitro potency of 2 LNA-modified DNA oligonucleotide anti-miRs (either 16 or 8 nucleotides in length), and compared it with a cholesterol-modified antagomir-15b ( Figure 2A ). The 16mer anti-miR is an LNA/DNA anti-miR complementary to the 5Ј end of miR-15b (L/D 15b). As a consequence of the high binding affinity for LNA-containing antisense oligonucleotides, biological activity is often attained with shorter LNA oligonucleotides. 18 We also tested an 8-mer LNA-anti-miR complementary to the seed region of the miR-15 family, which would be predicted to target all family members (tiny 15b). In parallel, we also tested an antagomir against miR-15b, which is the full-length complementary reverse sequence of miR-15b in which all nucleosides are 2Ј-O-Methyl (Ome) modified with the 5Ј terminal two and 3Ј terminal 4 bases containing a phosphorothioate internucleoside bond and a 3Ј cholesterol attached through a hydroxyprolinol linker (Figure 2A ).
To test for functional activity, we generated luciferase reporters harboring a perfect binding site for the different miR-15 members (miR-15b, -16, and -195) , such that inhibition of endogenous miR-15 members in HeLa cells would lead to an increase in luciferase activity. We focused on these particular family members because they appeared to be most highly regulated in vivo ( Figure 1A ). Luciferase reporter assays indicated a dose-responsive derepression of the miR-15b luciferase reporter for all 3 oligonucleotide chemistries tested, with the L/D 15b being most efficacious and the antagomir-15b showing the least activity. As expected, based on sequence composition, tiny 15b also repressed miR-16 and -195 activity, whereas the L/D 15b preferentially inhibited miR-15b ( Figure 2B ). These data correlate with the knockdown efficiency for the miR-15 family members in cardiomyocytes, as measured by real-time PCR analysis ( Figure  2C ). Subsequent mRNA analysis of ADP-ribosylation factorlike protein 2 (Arl2), a defined miR-15 target, indicated a dose-dependent increase in response to increasing inhibition of the miR-15 family with tiny 15b in cardiomyocytes, whereas this response was absent after treatment with L/D 15b ( Figure 2D ).
miR-15 Inhibition Increases Cardiomyocyte Viability in Response to Hypoxia
Because miR-15 is upregulated in vivo in response to ischemic stress and potentially contributes to cardiomyocyte survival, we aimed to determine the effect of miR-15 in hypoxic myocytes and fibroblasts in culture. We were able to verify the conditions of hypoxia and hypoxia/reoxygenation by measuring creatine kinase levels (Supplemental Figure IV, A) and miR-210 and VEGFa expression in both cardiomyocytes and fibroblasts, all known to show an increase in expression in response to hypoxic injury (Supplemental Figure IV, B) .To examine the effect of miR-15 inhibition on cell survival/viability, we made use of the adenosine triphosphate (ATP)-based cytotoxicity assay, which utilizes the bioluminescent measurement of ATP present in metabolically active cells to assess cell viability (Supplemental Figure IV, C) . 19, 20, 21 Compared with normoxic myocytes (norm), miR-15b was induced in cardiomyocytes under hypoxic conditions (hyp), which was further enhanced by subsequent reoxygenation (reox) ( Figure 3A ). Both during hypoxia and hypoxia with subsequent reoxygenation, we achieved efficient knockdown for both L/D 15b and tiny 15b compared with control transfected cells as determined by real-time PCR analysis (Supplemental Figure IV, D) .
Our data show that tiny 15b in cardiomyocytes dosedependently increases cardiomyocyte cell survival both under hypoxic conditions and after hypoxia with subsequent reoxygenation as indicated by an increase in relative ATP levels ( Figure 3B ), which is absent in fibroblasts under the same conditions (Supplemental Figure IV, E) . Additionally, we measured cell viability during hypoxia and reoxygenation through 2 enzyme release assays. One is the LDH assay, which is a means of measuring number of cells through total cytoplasmic lactate dehydrogenase, and the second assay is the MTT assay, which is also a measure of cell health and viability. Both assays show that tiny 15b increases cells viability under hypoxic conditions in vitro ( Figure 3C and 3D) . The increase in myocyte survival corresponded to a dose-dependent increased in Arl2 during hypoxia and an increase in Bcl2 during hypoxia, which became even more pronounced during reoxygenation (Figure 3E ). Whereas L/D 15b also increased the expression of Arl2, there was only a moderate effect on Bcl2 expression, making it tempting to speculate that the additional increase in Bcl2 is required to establish the protective effects on cardiomyocytes during hypoxia as seen for tiny 15b.
Silencing of miR-15 Family Members in Murine Cardiac Tissue by LNA-Modified Anti-miRs
Next, we examined whether LNA-anti-miRs were able to silence cardiac miR-15 family members in vivo. Because the final goal would be to inhibit miR-15 during a stress-induced increase of miR-15b, mice received angiotensin II 3 days before anti-miR treatment to elevate cardiac miR-15b levels (Supplemental Figure V, A) . Sin- gle intravenous injections of doses ranging from 0.033 mg/kg to 33 mg/kg of L/D 15b or equal molar amounts of tiny 15b through the tail vein resulted in dose-dependent repression of cardiac miR-15b 1 week after injection, as determined by real-time PCR analysis. The L/D 15b anti-miR showed the highest efficiency in antagonizing miR-15b ( Figure 4A and Supplemental Figure V, B ). Real-time PCR analysis for additional family members showed that 1 week after administration the targeting efficiency of tiny 15b was more distributed over the family with the exception of miR-15a, whereas the truncated L/D 15b anti-miR preferentially targeted miR-15b ( Figure 4B and Supplemental Figure V, B) . Currently, we have no explanation for the detected increase in miR-195 in response to the low dose of tiny 15b. The efficient knockdown of miR-15 family members was confirmed by Northern blot analysis for miR-16 ( Figure 4C) . Notably, we observed an upshift of miR-16 in the presence of tiny 15b when we used an LNA-probe that spanned the entire length of the miR-16 sequence. This upshift reflects the formation of a stable heteroduplex between miR-16 and the LNA anti-miR. Although Northern analysis shows efficient inhibition of miR-16 with the L/D 15b anti-miR, this oligonucleotide covers too much of the miRNA for the probe to bind and showed the anti-miR-miRNA heteroduplex. The injected animals showed no evidence of LNAassociated toxicities or histopathologic abnormalities in the heart, liver, or kidneys (data not shown).
Biodistribution data for the L/D 15b anti-miR were collected using a sandwich hybridization assay, using 2ЈOme modified capture and detection probe. Within 6 to 12 hours after intravenous delivery, the majority of the anti-miR cleared from the plasma for both the 1 and 33 mg/kg doses but remained detectable until 168 hours (1 week) after injection ( Figure 4D ). Cardiac detection of the anti-miR indicated high levels of anti-miR for the first 6 -12 hours (probably because of the level of anti-miR in the circulation), after which substantial amounts remained present in the heart at a relatively steady level of detection ( Figure 4E ). Cardiac detection 1 week after administration was dose-dependent ( Figure 4F ), whereas higher levels of anti-miR could be detected in liver and kidney ( Figure  4G ). Using a competition assay, comparable data analysis was performed on the tiny 15b treated samples, which indicated equivalent biodistribution data for tiny 15b (Supplemental Figure VI) .
To determine whether the route of administration influenced the inhibitory capacity of the anti-miRs, we compared intravenous, intraperitoneal, subcutaneous, and gavage administration side-by-side. These studies showed comparable inhibition 4 days after a single intravenous, intraperitoneal, or subcutaneous administration of both L/D 15b and tiny 15b. Gavage delivery also resulted in cardiac inhibition of miR-15b, albeit with a lesser efficiency (Supplemental Figure VII) .
In Vivo Silencing of miR-15 in Porcine Cardiac Tissue
To verify whether we could extrapolate the murine knockdown data of the LNA-modified anti-miRs to a larger animal model, we delivered increasing doses of L/D 15b or tiny 15b to pigs intravenously through the ear vein (Table) . Four days after injection, both real-time PCR and Northern blot analysis on biopsies taken from the left ventricle indicated that 1.0 mg/kg of L/D 15b was sufficient to inhibit miR-15b in the porcine heart by greater than 90% ( Figure 5A and 5B) . Northern blot showed that L/D 15b preferentially inhibited miR-15b ( Figure 5B ), whereas tiny 15b inhibited miR-15b and miR-16 as potently ( Figure 5C and 5D) , just as was seen in vitro and in mice. Parallel real-time PCR analysis on the left ventricle (LV), septum (Sep) or right ventricle (RV), indicated that the knockdown efficiency was comparable in different portions of the heart (Supplemental Figure VIII) . Both 1 and 4 days after intravenous delivery, tiny 15b induced efficient silencing of miR-15 members, as indicated by both real-time PCR and Northern blotting ( Figure 5C and 5D) .
Compared with the Northern blot data, real-time PCR appears to underestimate miR-15b inhibition, probably the result of a disruption of the anti-miR-miRNA binding during the PCR procedure. Tissue distribution data for Tiny 15b was dosed at equal molar amounts of 1, 3.3, and 10 mg/kg of L/D 15b. both chemistries in different portions of the heart indicate comparable dose-dependent detection at days 1 and 4 for tiny 15b in LV, RV, and Sep, which corresponds well to the detected quantities for L/D 15b at day 4 when dosed with equal molar amounts ( Figure 5E ). The plasma and tissue distribution data look identical to the murine data when dosed with a comparable amount of anti-miR (data not shown).
All mice tolerated the anti-miR or control oligo well and exhibited normal behavior, as determined by activity level and grooming throughout the study. Compared with saline, anti-miR-15b did not induce changes in body or tissue weights up to 6 weeks after dosing (data not shown). Both L/D 15b and tiny 15b did not change serum levels of the alanine aminotransferase and aspartate aminotransferase liver enzymes in pigs (Supplementary Figure IX, A) , nor were there any observable abnormalities histologically, suggesting that the oligonucleotides do not induce any overt toxicities (Supplemental Figure IX, B ).
miR-15 Inhibition Protects Against Ischemia-Induced Injury
To test the functional relevance of miR-15 inhibition during ischemia-reperfusion injury, we injected mice at the onset of reperfusion after 75 minutes of ischemia intravenously with tiny 15b, control oligo, or vehicle control (saline). The extent of myocardial infarction was determined 24 hours after reperfusion and indicated that treatment with tiny 15b during reperfusion resulted in a significant decrease in infarct size compared with either saline or control oligo, whereas there were no observable differences in area at risk ( Figure 6A and 6B ). Real-time PCR analysis on the ischemic region of the heart showed that miR-15b was induced after an ischemic event and that 0.5 mg/kg of tiny 15b resulted in a 72% reduction of cardiac miR-15b levels in the ischemic region 24 hours after reperfusion ( Figure 6C ). Hemodynamic analysis 24 hours after ischemia shows a significant increase in LV end-diastolic pressure, which was absent in response to tiny 15b treatment ( Figure 6D ). Microarray analysis on saline, tiny 15b, or control injected animals after ischemia-reperfusion indicates an overrepresentation of negative regulators of cell death upregulated in the tiny 15b-treated group ( Figure 6E and Supplemental Tables III  and IV) . Although the intersample variation between the groups was quite large, 23 TargetScan-predicted targets of the miR-15 family were found by microarray analysis to be derepressed with tiny treatment compared with saline treatment and with tiny treatment compared with control oligo treatment (Supplemental Figure X) . Real-time PCR analysis for 2 direct miR-15 targets, Pdk4 and Sgk1, confirms the microarray analysis and indicate a trending derepression after treatment with tiny 15b (data not shown). The regulation of these genes might be relevant because Pdk4 is a key regulator of mitochondrial function that has been shown to be decreased during hypertrophic remodeling, 22 whereas SGK1 is regulated in response to biomechanical stress and has been shown to inhibit cardiomyocyte apoptosis. 23 Functional analysis by echocardiography 2 weeks after induction of the ischemic injury indicates that tiny 15b treatment resulted in a significant improvement in ejection fraction, which corresponded with a decrease in both end-systolic and end-diastolic LV volumes ( Figure 6F ). The improvement in function parallels with a decrease in cardiac fibrosis in response to miR-15 inhibition 2 weeks after injury ( Figure 6G ). Combined, these data indicate that low doses of tiny 15b during reperfusion can reduce infarct size and improve cardiac function in response to ischemia-reperfusion, which is likely to be at least partially due to a derepression of antiapoptotic genes in response to miR-15 inhibition.
Discussion
Our data show a dynamic time-dependent and regional regulation of miRNAs in porcine cardiac tissue in response to ischemic damage. These changes in porcine cardiac tissue show a large overlap with changes found in a comparable setting in mice and human (reviewed in References 15, 24, and 25). 15, 24, 25 Most studies to date have shown a decrease in the miR-30 and miR-29 family in response to ischemia, whereas miR-21, miR-199a, miR-210, miR-320, miR-214, miR-92a, and multiple members of the let-7 family consistently show an increase. Although the decrease in the myocyte-specific myo-miRs in the ischemic porcine samples (miR-208a, -208b, and 499) specifically in the infarcted region might be due to a relative decline in myocyte subpopulation, further examination is warranted to determine whether this decreased detection is the result of a regulated process.
Among the regulated miRNAs in the infarcted region is the miR-15 family, which has been implicated in the regulation of cell survival and turnover. 26 Previously, we showed that ␣MHC-driven, cardiomyocyte-specific overexpression of the miR-15 family member miR-195 resulted in cardiac dilation and premature death around 3 weeks of age. Based on these observations, the proposed function of the miR-15 family and the increased expression in response to hypoxia, we aimed to assess the biological function of the miR-15 family in the setting of ischemic heart disease. In the heart, Bcl2 is involved in myocyte cell loss and contributes to a variety of cardiac pathologies, including heart failure and those related to ischemia/reperfusion injury. 27, 28 Previously, miR-15b was shown to increase cardiomyocyte survival in vitro by targeting Arl2, an important regulator of mitochondrial integrity. 6 Although our data confirm that the miR-15 family targets both Bcl2 and Arl2 in cardiomyocytes, the increase in myocyte survival during hypoxia and the protective effect during ischemia-reperfusion on miR-15 inhibition probably is due to the combined effect of many additional gene regulatory changes.
To date, several antisense oligonucleotides have been proven to be efficacious in silencing miRNAs in vivo. 8 -12 Whereas cholesterol conjugated antagomirs have been the most widely used experimental approach to inhibit miRNAs, including for cardiac indications, our data indicate LNAmodified oligonucleotide chemistries to be more potent in inhibiting miR function. LNA is a nucleic acid modification that introduces a thermodynamically strong duplex formation with oligonucleotides while enhancing specificity toward complementary RNA or DNA, hence allowing for shorter molecules. 8, 9 Because microRNA families are frequently more homologous toward their 5Ј region, designing a smaller molecule to target the 5Ј portion of a miRNA allows for combined targeting of multiple family members in parallel, 29 which was confirmed by our data. The therapeutic applicability of systemically delivered LNA-modified anti-miRs has been reported in nonhuman primates, where inhibition of the liver-expressed miR-122 led to an improvement in hepatitis C virus-induced liver pathology in chronically infected chimpanzees. 12 Recently, we showed LNA-modified oligos to be efficacious in inducing sustained and potent silencing of Figure 6 . miR-15 inhibition reduces infarct size and improves function in response to ischemia. A, Representative images after TTC staining indicate that although the area at risk (AAR, red and white) is comparable between the different treatment groups, the infarcted area (IA, white) is smaller in the tiny 15b-treated animals (control indicates control oligonucleotide). B, Quantification of cross sections of the infarcted hearts indicate that the AAR is Ϸ50% of the LV for all 3 treatment groups, whereas administration of 0.5 mg/kg of tiny 15b during reperfusion results in a significant reduction in infarct size compared with either saline or control oligo (*PϽ0.05 versus saline and control by ANOVA; control indicates control oligonucleotide). C, Realtime PCR analysis on tissue of the ischemic region 24 hours after reperfusion indicates inhibition of miR-15b in response to tiny 15b treatment (*PϽ0.05 versus saline and control oligonucleotide treated by ANOVA). D, Left ventricular end-diastolic pressure recordings 24 hours after reperfusion reveals an increase with saline treatment and a reduction with tiny 15b treatment (control indicates control oligonucleotide, *PϽ0.05 versus sham Kruskal-Wallis test). E, Ontology analysis of transcripts upregulated Ն1.5fold in the ischemic region of hearts 24 hours after reperfusion treated with tiny 15b treatment compared with saline, based on microarray profiling. Negative regulators of apoptosis and cell death are significantly overrepresented. F, Echocardiography shows a reduction in ejection fraction (EF) and increases in LV volumes 2 weeks after infarct, all of which are significantly improved in response to tiny 15b treatment (*PϽ0.05 versus saline and control by ANOVA for EF and LVESV, versus saline only LVEDV; sham indicates no ischemia/reperfusion; control, control oligo). G, Representative images of Picrosirius red-stained cross sections demonstrate a reduction in collagen content of the left ventricle 2 weeks after reperfusion with tiny 15b treatment. Quantification of fibrosis as a percentage of total left ventricular area reveals a statistically significant reduction in the tiny 15b-treated group (*PϽ0.05 versus saline-treated by ANOVA). LV indicates left ventricle. cardiac expressed miRNAs. 30, 31 Interestingly, the route of administration for these LNA-modified anti-miRs for cardiac targeting is flexible as subcutaneous and intravenous delivery induces a comparable miR-15b inhibition.
Single injections of low amounts of anti-miR induce a potent yet reversible inhibitory effect on their cardiac miRNA target. Because most miRNAs are expressed in many different tissue types, this short duration of action might be beneficial for acute situations, such as protecting myocytes during ischemic injury, to prevent potential side effects caused by miRNA inhibition in extracardiac tissues. More chronic indications probably will warrant multiple doses of anti-miR to sustain inhibition of miRNA, in which case delivery might become more relevant for the ubiquitously expressed miRNAs.
Although we are only just beginning to gain some insights into therapeutic regulation of miRNAs and much more remains to be learned, the fact that they are important regulators during cardiovascular disease together with the feasibility to potently inhibit specific miRNAs, makes them exciting new candidates to target in the setting of heart disease.
